peptide confessions

Canada \u00b7 Ozempic

Ozempic for weight loss in Canada: what's allowed and what's covered.

Ozempic is the best-known semaglutide brand, and many Canadians search for it to lose weight. The short answer: Ozempic is approved in Canada for type 2 diabetes, not weight loss. Wegovy is the same ingredient approved for weight management. Here is what that means for prescriptions and coverage.

Last reviewed October 15, 2026against Health Canada's Drug Product Database and provincial formularies.

Ozempic vs Wegovy for weight loss

OzempicWegovy
IngredientSemaglutideSemaglutide
Canadian indicationType 2 diabetesChronic weight management
Generic availableYes, since April 2026Yes, since June 2026
Public coverage for weight lossNoNo

More: Ozempic vs Wegovy in Canada and generic semaglutide.

Off-label prescribing

Canadian prescribers can sometimes prescribe a drug outside its approved use when they judge it appropriate. That is a clinical decision, not something a website can make for you. Two practical limits: public drug plans only pay for approved, listed uses, and the authorized weight-management options (Wegovy, its generic and Zepbound) exist for people without diabetes.

Why public plans won't cover Ozempic for weight loss

  • Ontario: Ozempic is a Limited Use benefit for type 2 diabetes only.
  • British Columbia: Special Authority requires type 2 diabetes and inadequate control on metformin.
  • Alberta: special authorization requires type 2 diabetes after metformin and a sulfonylurea.
  • Wegovy isn't publicly covered either: BC lists it as a non-benefit and Ontario doesn't list it.

What the weight-loss trial showed

In STEP 1(New England Journal of Medicine, 2021), adults with obesity or overweight and no diabetes took weight-management semaglutide or placebo for 68 weeks alongside lifestyle support. Average weight change was about −14.9% with semaglutide versus −2.4% with placebo. Gastrointestinal side effects such as nausea and diarrhea were the most common. See Ozempic side effects in Canada.

What semaglutide users report

  • 37 published anonymous semaglutide confessions; 5 mention at least one side effect.
  • 12 mention Ozempic, Wegovy or Rybelsus by name.
  • Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.

Most-mentioned side effects (share of semaglutide confessions):

  • Burping: 5.4% (2)
  • Nausea: 5.4% (2)
  • Vomiting: 5.4% (2)
  • Anxiety or panic: 2.7% (1)
  • Constipation: 2.7% (1)

Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: semaglutide side-effects report.

By province and city

Related

Frequently asked questions

Is Ozempic approved for weight loss in Canada?
No. Ozempic's Canadian indication is type 2 diabetes. The semaglutide product Health Canada authorized for chronic weight management is Wegovy, plus its generic equivalent authorized in June 2026.
Can a doctor prescribe Ozempic for weight loss in Canada?
Prescribing a drug outside its approved use (off-label) is a clinical decision for a licensed prescriber. Public plans won't pay for it, and some private plans limit Ozempic to diabetes.
Can I get Ozempic without diabetes in Canada?
Some prescribers do prescribe it off-label, but provincial coverage criteria in Ontario, BC and Alberta all require type 2 diabetes. For weight management without diabetes, Wegovy and Zepbound are the authorized options.
How much weight do people lose on semaglutide?
In the STEP 1 trial of weight-management semaglutide (Wegovy strength) in adults without diabetes, average weight change over 68 weeks was about -14.9% versus -2.4% with placebo. Individual results vary widely.
Does this page recommend a clinic, product or dose?
No. We don't list clinics, sellers, prices or doses, and nothing here is medical advice. Talk to a licensed Canadian prescriber or pharmacist.

Sources

  1. Drug Product Database: Ozempic and Wegovy listings (health-products.canada.ca)
  2. Health Canada: first generic semaglutide for weight loss, June 2026 (canada.ca)
  3. Wilding et al. STEP 1, New England Journal of Medicine 2021 (doi.org)
  4. BC PharmaCare Special Authority: semaglutide for diabetes (gov.bc.ca)
  5. Alberta Blue Cross: GLP-1 special authorization criteria (ab.bluecross.ca)
  6. Ontario Drug Benefit Formulary search (formulary.health.gov.on.ca)

General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →

the week's best confessions, in your inbox.